Go back
Gnosco on the way to Australia

By successfully gaining funding from the Business Sweden Catalyst Program, GNOSCO will enter the Australian healthcare market and engage with partners “down under” with its product Dermicus.

“The World Cancer Fund ranks Australia with the highest number of annual skin cancer cases globally, so it’s a vital healthcare market for us. We have fantastic proven benefits from our years of experience in Sweden, including 8 out of 10 patient cases being diagnosed within 24 hours and surgery to excise a melanoma is on average four days after the first visit,” says Philip Daniels-May, Business Development Director

Read more here.